Skip to main content
. Author manuscript; available in PMC: 2010 Oct 1.
Published in final edited form as: Gynecol Oncol. 2009 Jul 31;115(1):112–120. doi: 10.1016/j.ygyno.2009.06.031

Figure 1.

Figure 1

Representative western immunoblots of patient immunoreactivity with cellular proteins from ovarian tumors and normal ovarian epithelium. Recognition of cellular proteins used patient serum diluted 1:100. Representation sera were obtained from patients (Panel A) with a benign ovarian mass (serous adenoma), (Panel B) early stage (Stage I) and (Panel C) late stage (Stage IIIc) ovarian cancers.